Search Results

You searched for : Lynparza

	Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer ... Jun 24
	LYNPARZA (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer Only PARP Inhibitor to Demonstrate Overall Survival Versus New Hormonal Treatments in BRCA1/2-Mutated Advanced Prostate Cancer... Jun 24
	LYNPARZA (olaparib) Receives Three New Approvals in Japan LYNPARZA has been approved in Japan for the treatment of three types of advanced cancer: ovarian, prostate and pancreatic cancer.... Dec 28
	Lynparza approved in the EU as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer Lynparza in combination with bevacizumab demonstrated as a treatment for the treatment of HRD-positive advanced Ovarian Cancer... Nov 05
	LYNPARZA Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer Only PARP Inhibitor to Demonstrate Overall Survival Versus New Hormonal Agent Treatments in BRCA1/2-Mutated mCRPC... Nov 05
	DCGI approves AstraZeneca Olaparib tablets for ovarian and breast cancer AstraZeneca's patented olaparib for ovary and breast cancer now in India... Aug 20
	Positive About COVID-19 Vaccine, Says UK Pharma Firm AstraZeneca has already reached deals with countries to make more than 2 billion doses of its COVID-19 vaccine with Oxford Univeristy ... Jul 31
	AstraZeneca-Merckâ€™s Lynparza wins EU approval for pancreatic cancer Pancreatic cancer is a rare, life-threatening disease with the lowest survival rate among the most common cancers. ... Jul 08
8 Matching result(s) found!

-Advertisements-

Trending Now
	Plant-Based Diets and Prostate Cancer: New UCSF Study Shows Promising ResultsMay 16, 2024
	National Medical Commission Approves 112 New Medical CollegesMay 16, 2024
	Study Suggests That Chemotherapy Results in Physical Decline for Older Women with Breast CancerMay 16, 2024
	Google DeepMind's AlphaFold 3: Revolutionizing Drug Discovery with AIMay 16, 2024
	Hester Biosciences Ltd reports Consolidated Revenue growth of 18% at Rs. 79.3 crore, EBITDA up 37% to Rs. 16.4 crore and Net Profit up 12% to Rs. 6.40 crore in Q4FY24May 16, 2024
	Akshay Tritiya Parna Mahotsav heldMay 16, 2024
	IT Minister Sridhar Babu to grace the 10th National Facilities Managers Summit-2024, to be held in the cityMay 15, 2024
	Alarming Study Reveals Cancer-Causing Chemicals in Car InteriorsMay 15, 2024
	India's Thalassemia Challenge: The Importance of Early Screening and TreatmentMay 15, 2024
	The Dangers of Ultra-Processed Foods: A 30-Year Study Raises AlarmsMay 15, 2024
	Unique Genetic Risk Factors for Breast Cancer Found in African Ancestry StudyMay 15, 2024
	AsiaMedic partners with Sunway to establish new diagnostic imaging centreMay 14, 2024
	Kamineni Doctors Successfully Remove Bone Stuck Near Heart in Elderly PatientMay 14, 2024
	On International Nurses Day, American Oncology Institute (AOI) launches #TheExtraordinaryCareGiver Campaign as Tribute to Oncology NursesMay 14, 2024
	Shiprocket announces Shiprocket Growth Academy to upskill 100,000 Indian MSMEs through eCommerce learningMay 14, 2024
	5 baby essential gifts for new and expecting momsMay 13, 2024
	BLUM India launches its first State-of-the-Art Experience Centre in HyderabadMay 13, 2024
	Cipla Eyes Eli Lilly Partnership to Tap Growing Demand for Obesity Drugs in IndiaMay 13, 2024
	Setback for Organ Transplantion: First Human to Receive Pig Kidney DiesMay 13, 2024
	Why AstraZeneca is Withdrawing the Covid-19 Vaccine Globally: Explained May 13, 2024

Search Results

Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer

LYNPARZA (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

LYNPARZA (olaparib) Receives Three New Approvals in Japan

Lynparza approved in the EU as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer

LYNPARZA Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer

DCGI approves AstraZeneca Olaparib tablets for ovarian and breast cancer

Positive About COVID-19 Vaccine, Says UK Pharma Firm

AstraZeneca-Merckâ€™s Lynparza wins EU approval for pancreatic cancer

Trending Now